OpGen (OPGN) AI Stock Analysis

• Market Cap: $40.78M
• Dividend Yield: N/A
• Average Volume (3M): 4.27K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.89
• Revenue Growth: -58.77%
• EPS Growth: 80.26%
• Country: US
• Employees: 85
• Sector: Healthcare
• Sector Strength: 40
• Industry: Medical - Diagnostics & Research
• EPS (TTM): -12.96
• Shares Outstanding: 10,068,111
• 10 Day Avg. Volume: 2,833
• 30 Day Avg. Volume: 4,272
• PEG Ratio: -0.08
• Price to Book (P/B): 7.73
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -6.39
• Enterprise Value/Market Cap: 1.01
• Enterprise Value/Revenue: 4.40
• Enterprise Value/Gross Profit: 745.96
• Enterprise Value/Ebitda: -0.46
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 40 Underperform
• Price Target: ―

OpGen's overall stock score is low due to significant financial challenges, including declining revenues, negative profitability, and reliance on external financing. Technical indicators suggest a bearish trend with potential overbought conditions, and valuation metrics highlight unprofitability. These factors collectively indicate substantial risk and uncertainty in the company's near-term performance.

OpGen Business Overview & Revenue Model

Company Description

OpGen, Inc. is a precision medicine company focused on combating infectious diseases through its innovative molecular diagnostics and informatics technology. The company operates in the biotechnology and healthcare sectors, providing advanced solutions for the detection and treatment of multi-drug resistant pathogens. OpGen's core products include the Acuitas AMR Gene Panel, which identifies bacterial pathogens and resistance genes, and the Unyvero platform, a rapid diagnostic system for severe infections.

How the Company Makes Money

OpGen generates revenue primarily through the sale of its diagnostic products and services. The company's revenue model is based on selling its molecular diagnostic tests, such as the Acuitas AMR Gene Panel and the Unyvero platform, to hospitals, laboratories, and healthcare providers. Additionally, OpGen earns income from service agreements, where it provides testing services using its proprietary technology. Key partnerships with healthcare institutions and collaborations with other biotech firms enhance its market reach and contribute to its earnings. The company's focus on addressing challenges related to antimicrobial resistance creates a demand for its products, further driving its revenue streams.

OpGen Financial Statement Overview

Summary

OpGen is struggling financially with declining revenues, consistent losses, and cash flow challenges. While there are some signs of improvement in equity, high leverage and dependency on external financing raise concerns about financial sustainability and risk management. Efforts to improve operational efficiency and cost management are crucial for future stability.

Income Statement

OpGen experienced a significant decline in revenue from 2023 to 2024 TTM, with a negative gross profit margin indicating cost challenges. The net profit margin is also negative due to consistent losses, reflecting ongoing unprofitability. EBIT and EBITDA margins are similarly negative, highlighting operational inefficiencies and high expenses relative to revenue.

Balance Sheet

The balance sheet shows improvement in stockholders' equity moving from negative to positive in 2024 TTM, improving its financial stability. However, the company still faces high leverage with a significant amount of total debt relative to equity, posing risks of financial instability.

Cash Flow

Cash flow remains a concern with negative operating and free cash flow, indicating cash outflows that surpass cash inflows from operations. Although there is substantial financing inflow, reliance on external funding increases financial risk and sustainability concerns.

Breakdown	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement
Total Revenue	3.42M	2.61M	4.31M	4.21M	3.50M
Gross Profit	-90.69K	-817.00K	1.46M	365.95K	1.87M
EBITDA	-29.51M	-32.38M	-27.25M	-20.34M	-11.34M
Net Income	-32.67M	-37.28M	-34.81M	-26.21M	-12.45M
Balance Sheet
Total Assets	1.88M	25.83M	71.67M	49.75M	10.42M
Cash, Cash Equivalents and Short-Term Investments	1.15M	7.44M	36.08M	13.36M	2.71M
Total Debt	13.04M	14.84M	25.18M	22.85M	3.16M
Total Liabilities	13.44M	18.25M	30.45M	28.56M	6.13M
Stockholders Equity	-11.56M	7.58M	41.22M	21.19M	4.29M
Cash Flow
Free Cash Flow	-15.12M	-21.04M	-23.46M	-23.53M	-11.54M
Operating Cash Flow	-14.32M	-20.45M	-21.48M	-23.40M	-11.51M
Investing Cash Flow	-800.41K	-590.77K	-1.98M	-1.06M	-2.50M
Financing Cash Flow	8.37M	-6.74M	47.45M	34.09M	12.17M

OpGen Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 4.60
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OPGN, the sentiment is Positive. The current price of 4.6 is below the 20-day moving average (MA) of 4.74, below the 50-day MA of 4.78, and above the 200-day MA of 2.63, indicating a neutral trend. The MACD of -0.05 indicates Positive momentum. The RSI at 47.85 is Neutral, neither overbought nor oversold. The STOCH value of 66.87 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for OPGN.

OpGen Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CDNA	77 Outperform	$1.06B	16.66	21.57%	―	25.92%	―
OSUR	57 Neutral	$232.63M	25.27	-7.77%	―	-46.95%	-237.44%
Sector *	52 Neutral	$7.39B	>-0.01	-63.86%	2.36%	16.15%	0.36%
QDEL	47 Neutral	$1.89B	―	-10.59%	―	-3.18%	81.18%
OPGN	40 Underperform	$40.78M	―	-331.94%	―	-58.77%	80.26%
TTOO	35 Underperform	$3.22M	―	366.81%	―	-30.19%	97.74%

OpGen Corporate Events

OpGen Appoints New COO and Company Secretary

OpGen, Inc. appoints Mohd Azham Azudin as COO and Gillian Tan Rou Yee as Company Secretary, bringing extensive experience in private equity and corporate law, respectively. Azudin, with over 25 years in investment roles, will earn a base salary of $50,000, potentially convertible to equity. Tan, a seasoned legal professional, will receive $25,000, also convertible to equity, highlighting OpGen’s strategic focus on experienced leadership and flexible compensation structures.